Kania Brooke, Mekheal Erinie, Roman Sherif, Mekheal Nader, Kumar Vinod, Maroules Michael
St. Joseph's University Medical Center, Paterson, NJ, USA.
Eur J Case Rep Intern Med. 2022 Feb 18;9(2):003125. doi: 10.12890/2022_003125. eCollection 2022.
Complete blood counts are frequently collected from cancer patients, but laboratory findings may be misleading. Secondary polycythemia can occur in renal cell carcinoma (RCC) due to erythropoietin (EPO) stimulation. Therefore, complete blood counts should be closely monitored to prevent complications such as thrombosis. We discuss the case of a 47-year-old man with metastatic RCC who presented with secondary polycythemia that improved with chemotherapy. His secondary erythrocytosis was anticipated, but his haemoglobin levels were lower than expected after therapy. This article discusses the treatment and diagnosis of secondary polycythemia in patients with RCC.
Haemoglobin and haematocrit levels should be closely monitored in renal cell carcinoma (RCC) patients as they may develop secondary polycythemia as a result of their malignancy.Secondary polycythemia can be managed with chemotherapy and immunotherapy in RCC, with anti-cancer agents preventing the need for phlebotomy.Chemotherapy may benefit RCC patients by decreasing tumour burden, preventing progression, and by lowering haemoglobin levels, thus improving secondary polycythemia.
癌症患者经常进行全血细胞计数，但实验室检查结果可能会产生误导。由于促红细胞生成素（EPO）刺激，肾细胞癌（RCC）患者可能会出现继发性红细胞增多症。因此，应密切监测全血细胞计数以预防血栓形成等并发症。我们讨论了一例47岁转移性肾细胞癌男性患者，其出现继发性红细胞增多症，化疗后病情改善。他的继发性红细胞增多症在意料之中，但治疗后血红蛋白水平低于预期。本文讨论了肾细胞癌患者继发性红细胞增多症的治疗和诊断。
肾细胞癌（RCC）患者应密切监测血红蛋白和血细胞比容水平，因为他们可能因其恶性肿瘤而发生继发性红细胞增多症。肾细胞癌的继发性红细胞增多症可用化疗和免疫疗法治疗，抗癌药物可避免放血治疗的必要性。化疗可能通过减轻肿瘤负担、防止病情进展以及降低血红蛋白水平来使肾细胞癌患者受益，从而改善继发性红细胞增多症。
